July 19, 2023
FDA: Class I recall of Quidel Triage Cardiac Panels
Editor's Note
The Food and Drug Administration (FDA), on July 17, identified the recall by Quidel Cardiovascular Inc of its Quidel Triage Cardiac Panels as Class I, the most serious.
The recall was initiated because of reports of inaccurate tests showing lower than expected troponin levels in samples. A falsely low or negative troponin level may cause a delayed or missed diagnosis of myocardial infarction.
The company reports 41 complaints, no injuries, and no deaths related to this issue.
Distribution dates: Beginning November 1, 2022.
Free Daily News
- Report: Consistent, purposeful manager-team engagement reduces RN turnover
- Death, hospital readmission less likely for women treated by female doctors
- FDA announces class 1 recalls for infusion pumps, anesthesia workstation
- Study finds workforce readiness gap in new nurses
- Joint replacement manufacturer recalls products after FDA packaging warning
- Gene-edited pig kidney, heart pump combined in transplant surgery milestone
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging